Wuhan Unveils Two Brain-Computer Interface Tech Platforms

Wuhan's move is notable less for the platforms themselves than for the funnel they create: animal work and investigator-initiated studies feeding into randomized, double-blind GCP trials is the kind of infrastructure that turns lab demonstrations into regulated clinical products. Tying that to a scenario laboratory aimed at entertainment, education and high-risk industries signals an intent to commercialize BCI beyond the hospital, which puts Wuhan in the same conversation as other Chinese hubs courting neurotech. The open question is whether the clinical trial capacity actually attracts sponsor-backed programs or remains a domestic research channel.